Seaport Therapeutics’ Glyph platform faces its real test as GlyphAllo advances in depression
Seaport Therapeutics’ GlyphAllo data sharpen the case for oral neuroactive steroids in depression. Read what this could change next.
Pharma & Biotech
Pharma & Biotech
Can Corcept’s Lifyorli become a real new standard in platinum-resistant ovarian cancer after FDA approval?
Corcept’s Lifyorli won FDA approval in platinum-resistant ovarian cancer. Read what the survival data could change for clinicians, rivals, and regulators.
Pharma & Biotech
Can Merck’s $6.7bn Terns takeover turn TERN-701 into a post-Keytruda oncology pillar?
Merck is buying Terns for TERN-701. Read why this CML deal could reshape its hematology strategy and what risks still remain.
Medical Devices & Diagnostics
Pixee Medical receives CE mark for AR knee surgery system as FDA clearance opens U.S. ambulatory market
Pixee Medical's Knee+ NexSight receives CE mark. Analyse what AR guidance offers over robotics in total knee arthroplasty and what questions remain.
Medical Devices & Diagnostics
CorVista Health expands machine-learning diagnostics to INOCA with new ACC.26 poster data
CorVista Health presents machine-learned non-invasive INOCA detection data at ACC.26. Analysis of what this means for cardiology and women's heart care. Read more.
Medical Devices & Diagnostics
LUNA trial 2026: Spark Biomedical tests non-pharmacological device for heavy menstrual bleeding
Spark Biomedical launches LUNA Phase II trial evaluating wearable auricular neurostimulation for heavy menstrual bleeding. What the study design reveals.
Pharma & Biotech
Nasus Pharma Ltd. expands intranasal platform as NS002 moves closer to regulatory pathway
Nasus Pharma Ltd. advances NS002 toward pivotal trials with faster epinephrine delivery. Discover what this means for anaphylaxis care.
Pharma & Biotech
IMUNON advances Phase 3 with stronger survival data, signaling a shift in ovarian cancer immunotherapy
IMNN-001 shows improved survival in ovarian cancer. Find out what this means for Phase 3 success and future treatment strategies.
Pharma & Biotech
Can VeonGen Therapeutics validate VR-based endpoints as Stargardt trials move toward pivotal design
VG801 shows early vision gains in Stargardt disease. Find out what this means for gene therapy endpoints and regulatory pathways.
Pharma & Biotech
What AEON Biopharma Inc.’s analytical strategy reveals about the future of botulinum toxin biosimilars
AEON Biopharma advances ABP-450 biosimilar strategy. Discover what this means for BOTOX competition and future complex biologics markets.